Avodart (generic name: dutasteride) is the first dual acting 5 alpha-reductase inhibitor.
Avodart is found to be effective in reduction of the prostate size, improvement of urination, reduction of the risk of acute urinary retention and the need for surgical treatment.
Avodart is prescribed for the treatment of moderate and severe symptoms of benign prostatic hyperplasia of the prostate gland. Avodart is also used to reduce the risk of acute urinary retention and the need for surgical treatment in people with moderate and severe symptoms of benign prostatic hyperplasia of the prostate gland.
Mechanism of action
Avodart contains the active ingredient – dutasteride, which is a second generation 5-alpha reductase enzyme inhibitor, the enzyme that converts testosterone to showing much stronger action 5-a-dihydrotestosterone (DHT). Dutasteride is able to slow down both (1 and 2 type) of enzyme that is responsible for the conversion of testosterone into dihydrotestosterone (DHT) and reduce the concentration of dihydrotestosterone (DHT) in serum. DHT has been considered a factor causing both symptoms of BPH and male pattern baldness. As Avodart reduces the level of DHT, it is effective in treating the symptoms of BPH and male pattern baldness. As compared to a similar medication – Propecia (Finasteride), also acting preemptively on the transformation of testosterone into dihydrotestosterone – Avodart reduces DHT production by over 93%, while Propecia – only 66%. Inhibiting production of DHT leads to a reduction of dihydrotestosterone volume in prostate, resulting in a reduction in symptoms and reduce the risk of acute urinary retention and the need to surgical intervention.
Important information about Avodart and BPH
BPH is a progressive disease. There are a lot of scientific observations that exactly determined that fact. Therefore the need for long-term course of Avodart therapy is not a manifestation of the “weakness” of dutasteride against BPH. Meanwhile Avodart begins to act quickly – within the first month many patients reported improvement in urination. And only 6 months of the treatment will be sufficient for an objective evaluation of the effect of the therapy. 0.5 mg of Avodart daily in the first week of treatment is enough to reduce DHT levels by 85% and after 2 weeks – 90%.
Clinical efficacy of Avodart evaluated in three large-scale, placebo-controlled randomized studies. Two of them (ARIA3001, ARIA3002) conducted in the United States, and the third (ARIA3003) – in 19 countries. The total study involved 400 medical centers.
Dosage and administration
The capsules should be taken as a whole. Avodart can be taken with or without food. The effect is quite fast, but treatment should be continued for at least 6 months in order to objectively evaluate the effect of the drug.
Avodart capsules are for oral administration only. The dose and frequency of use of the medicine are determined by your doctor. Most often the prescribed dosage is one capsule of dutasteride (0.5 mg) daily. It may be taken either with or without food. The capsules should be swallowed whole and not chewed or opened, as contact with the contents of capsules may cause irritation of the mucous membrane of the mouth and throat. Before using this medicine, check the expiry date stated on the package and the blister. Do not use it after expiry date. Store the drug in a tightly closed container, out of the reach and sight of children, as required by the manufacturer. This medicine has been prescribed by your doctor to treat a specific disease…